Posted on 30 August 2012
Hospira, a big pharma company singed a definitive pharma partnering agreement to acquire an active pharmaceutical ingredient (API) manufacturing facility, together with an associated research and development (R&D) facility, from Orchid Chemicals & Pharmaceuticals for approximately $200 million.
Read the full story
Posted on 23 August 2012
A shortage of injectable drugs in the U.S. means India’s Strides Arcolab Ltd. (STR) could sell a division that makes generic cancer treatments and antibiotics for more than the entire company’s market value.
Read the full story
Posted on 06 June 2012
This report provides all the information you require to better understand Hospira and its partnering interests and activities over the past seven years. Read the full story
Posted on 16 August 2010
Biotech firms Roche, Genzyme, Athersys, Miltenyi Biotec, Hospira, Lonza and Life Technologies are joining the International Society for Cellular Therapy (ISCT) to launch a series of initiatives to create greater strategic alignment within the industry and drive late stage clinical development. More on the ISCT plans here
Posted on 08 July 2010
Genzyme Corp, which is attempting to fix quality-control problems involving its top medicines, will have Hospira Inc fill and package the drugs under a new supply agreement between the two companies, Genzyme said in a regulatory filing. Read the full story
Posted on 08 June 2010
Hospira and DURECT have entered into a licensing agreement to develop and commercialise DURECT's POSIDUR (SABER-bupivacaine a long-acting version of the anaesthetic bupivacaine currently in Phase III clinical trials. Read the full story
Posted on 05 January 2010
The agreement comes as Genzyme wrestles with manufacturing constraints that have led to shortages of two of its biggest-selling products.
Posted on 12 December 2009
Agreement to license, develop and commercialize ChemGenex's product candidate omacetaxine mepesuccinate, a novel targeted cytotoxic pharmaceutical product, in Europe, the Middle East and parts of Africa. Read the full story
Posted on 30 September 2009
Hospital products and generic drugmaker Hospira acquired worldwide rights to a generic version of the white blood-cell boosting drug filgrastim from Teva.